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4List of abbreviations
(c)PPT (central) polypurine tract
(h)CMV (human) cytomegalo virus
att sites attachment sites
BIV bovine immunodeficiency virus
BMM bone marrow-derived macrophages
BMV brome mosaic virus
CA capsid protein
CAEV caprine arthritis encephalitis virus
cDNA complementary DNA
CTE constitutive transport element
CTS central termination signal
dNTP deoxyribonucleotide triphosphate
EIAV equine infectious anemia virus
Env envelope glycoprotein
FIV feline immunodeficiency virus
Gag group specific antigen
GFP green fluorescent protein
gp glycoprotein
HIV human immunodeficiency virus
hrs hours
IN integrase
kb kilobases
kDa Kilodalton
LTR long terminal repeat
MA matrix protein
Min minutes
MOI multiplicity of infection
MVV maedi-visna virus
NC nucleocapsid
Nef negative factor
NLS nuclear localization signal
nts nucleotides
o/n over night
Pbs primer binding site
PCR polymerase chain reaction
pDNA plasmid DNA
PERT product-enhanced reverse
transcriptase assay
PIC pre integration complex
PM peritoneal macrophages
Pol polymerase
PR protease
rcf relative centrifuge force
RCR replication competent retrovirus
Rev regulator of expression of viral
proteins
rpm round per minute
RRE rev responding element
RT reverse transcriptase
RT room temperature
RTC reverse transcription complex
SIN self-inactivating
SIV simian immunodeficiency virus
SU surface glycoprotein
TAR transactivation response RNA
element
Tat transactivator of transcription
TM trans-membrane glycoprotein
TU/ml transducing units per mililiter
U unit
Vif viral infectivity factor
Vpr viral protein r
Vpu viral protein u
VSV-G vesicular stomatitis virus envelope
G glycoprotein
w/o without
WPRE woodchuck hepatitis post-
transcriptional response element
51.           Summary / Abstract
In contrast to other retroviruses, lentiviruses do not require mitosis for the efficient
integration of viral DNA into the host genome, and thus, they are able to transduce non-
dividing cells. To date, gene transfer to a wide variety of dividing and non-dividing
primary cells has been successfully performed.
In this study we evaluated the ViraPower™ T-REx™ Lentiviral Expression System
(Invitrogen) in terms of the efficient transduction of differentiated primary cells. This
system consists of a transfer expression vector containing the gene of interest, and a
three plasmid packaging system required for vector particle production. To assess the
transduction efficiency of viral preparations, the green fluorescent protein (GFP) was
used as a reporter gene.
The virus was produced according to the manufacturer’s protocol and the viral titers
were determined by selection of antibiotic-resistant cell clones, as recommended. By
this means, we obtained titers in the range of 5 – 9.7 x 103 transducing units/ml. The
achieved multiplicity of infection (MOI) was too low for the successful transduction of
primary cells.
Subsequently, we applied modifications to the original protocol in order to increase the
viral titers. These approaches for optimization included the use of a two plasmid
packaging system, the scale-up of the virus production by the increase of the total
amount of transfected cells and the concentration of viral supernatants by
ultracentrifugation. All approaches resulted in a clear improvement of the titer.
Consequently, the transduction of primary macrophages yielded a moderate to strong
expression of GFP.
In addition to the conventional titration, the reverse transcriptase (RT) activities of the
viral supernatants were determined by a product-enhanced reverse transcriptase
(PERT) assay analysis. The measured RT activity values were in accordance with the
transduction results of the primary cells.
In summary, we report the successful improvement of lentivirus production leading to
distinctly increased titers compared to the original protocol. As a result, primary
macrophages were efficiently transduced. In addition, we show, that the PERT assay is
a reliable method to predict the transduction capacity of lentiviral supernatants.
2.          Zusammenfassung
Lentiviren können im Gegensatz zu allen anderen Retroviren ihre virale DNS
unabhängig vom Zellteilungsstadium der Wirtszelle in das Wirtsgenom integrieren.
Dadurch können sie mitotisch inaktive Zellen transduzieren. Mittlerweile ist der
Gentransfer in eine Vielzahl von sowohl mitotisch aktiven als auch mitotisch inaktiven
Zellen erfolgreich nachgewiesen worden.
In dieser Arbeit haben wir getestet, ob das “ViraPower™ T-REx™ Lentiviral Expression
System” (Invitrogen) geeignet ist primäre Makrophagen effizient zu transduzieren.
Dieses System besteht aus einem Expressionsvektor, der das zu transferierende Gen
enthält, und einem Verpackungssystem bestehend aus drei Plasmiden, das für die
Vektorpartikelproduktion benötigt wird. Um die Transduktionseffizienz bewerten zu
können, verwendeten wir das grün fluoreszierende Protein (GFP) als Reportergen.
Die Virusproduktion und die Bestimmung der viralen Titer durch Selektion Antibiotika-
resistenter Zellklone wurden entsprechend dem Originalprotokoll durchgeführt. Mit
dieser Methode erhielten wir virale Titer von 5 bis 9.7 x 103 transduzierte Units/ml.
Aufgrund dieser niedrigen Titerwerte wurde kein ausreichendes Verhältnis von
infektiösen Viruspartikeln zu Zellen erreicht, welches zu einer erfolgreichen
Transduktion der Zellen geführt hätte.
In der Folge versuchten wir durch Modifikationen des Originalprotokolls die viralen Titer
zu erhöhen. Diese umfassten die Virusproduktion unter der Verwendung eines
Verpackungssystems bestehend aus zwei Plasmiden, eine Virusproduktion im größeren
Maßstab durch die Erhöhung der Anzahl der Virus produzierenden Zellen und die
Konzentration der viralen Überstände durch Ultrazentrifugation. All diese Ansätze
führten zu einem deutlichen Titeranstieg, sodass wir in primären Zellen eine mittlere bis
starke GFP Expression nachweisen konnten.
Zusätzlich zur konventionellen Titration wurde die Aktivität der viralen reversen
Transkriptase (RT) durch eine „product-enhanced reverse transcriptase“ (PERT)
Analyse bestimmt. Die gemessenen RT Aktivitäten stimmten mit den
Transduktionsergebnissen der primären Zellen überein.
Zusammenfassend berichten wir in dieser Arbeit von erfolgreichen
Optimierungsschritten des Originalprotokolls zur Produktion von Lentiviren, die zu
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7deutlichen Titeranstiegen führten. Dadurch konnten wir primäre Makrophagen effizient
transduzieren und zeigen, dass die PERT Analyse eine verlässliche Methode ist um die
Transduktionskapazität von lentiviralen Überständen einzuschätzen.
83.          Introduction
3.1.   Classification of lentiviruses
Lentiviruses belong to the large family of retroviruses. Retroviruses are enveloped
viruses carrying two copies of single-strand positive RNA. The virions are 80-100nm in
diameter and the comprised virion RNA is 7-12kb in size. The replicative strategy of the
Retroviridae includes the reverse transcription of the virion RNA into linear double-
stranded DNA, which is integrated into the host cell’s genome, hence the designation
“retro” [1].
Retroviruses are broadly divided into the categories simple and complex, according to
the organization of their genomes. Simple viruses carry only structural genes (gag, pol,
and env), whereas complex viruses additionally code for regulatory proteins. Defined by
evolutionary relatedness, retroviruses can further be divided into the genera Lentivirus,
Spumavirus and a group of  “oncogenic” viruses [2].
The name lentivirus (lentus, latin – slow) originates from the uniquely prolonged
incubation period needed for the virus to induce a disease. The genus Lentivirus
comprises a variety of primate (human immunodeficiency virus (HIV)-1 and 2, simian
immunodeficiency virus (SIV)) and non-primate viruses (Maedi-Visna virus (MVV), feline
immunodeficiency virus (FIV), equine infectious anemia virus (EIAV), caprine arthritis
encephalitis virus (CAEV) and bovine immunodeficiency virus (BIV)) [3].
3.2.   Structure of the lentiviral genome
The lentiviral genome consists of cis-acting sequences, which do not encode proteins,
and trans-acting viral elements encoding structural, regulatory, and accessory proteins.
Cis-acting determinants include long terminal repeats (LTRs), the packaging signal psi
(ψ), the rev-response element (RRE), the polypurine tract (PPT), and attachment (att)
sites.
LTRs are homologous regions at both ends of the lentiviral provirus, which are required
for virus replication, integration, and expression. LTRs can be divided into three regions,
U3, R, and U5. U3 comprises basal-, enhancer-, and modulatory-promoting elements.
9The R region is involved in the Tat-mediated transactivation (see 3.2.2). Furthermore,
the first nucleotide of the R region corresponds to the transcription initiation. LTRs also
contain signals for RNA capping and polyadenylation in the R region. U5 is sufficient for
reverse transcription and thus infectivity of viral particles. Psi is required for the
encapsidation of the genomic transfer RNA. The RRE interacts with the rev gene and is
essential for processing and the transport of viral RNAs. The PPT is necessary for
priming of the plus-strand synthesis and the att sites for viral DNA integration [2-4].
Besides the structural genes gag, pol, and env (see 3.2.1.), common to all retroviruses,
HIV-1 additionally comprises regulatory (tat, rev) (see 3.2.2.) and accessory genes (vif,
vpr, vpu, nef) (see 3.2.3.), involved in viral gene expression, viral particle assembly, and
infectivity (Fig. 1). HIV-1 has become the best-studied and most frequently used
lentiviral vector system (see 3.4.) [3].
Figure 1: Genome map of a lentivirus. The organization of the lentiviral genome and the localization of
the viral proteins are schematically depicted. Picture by C. Büchen-Osmond and J. Whitehead.
(http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/00.061.1.06.htm)
3.2.1.   Structural genes of HIV-1
Common to all retroviruses the HIV-1 genome encodes the three structural proteins
Gag (group-specific antigen), Pol (polymerase), and Env (envelope glycoprotein). Gag
and Pol proteins are initially synthesized as polypeptide precursors p55 Gag and p160
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Gag-Pol. During or after virus budding from the host cell the precursors are cleaved by
the viral protease into mature products. The cleavage of the 55-kDa Gag precursor
generates the structural proteins p17 matrix (MA), p24 capsid (CA), and p7
nucleocapsid (NC) (Fig. 1). The processing of the 160-kDa Gag-Pol precursor
generates the viral enzymes p12 viral protease (PR), p51/66 reverse transcriptase (RT),
and p31 integrase (IN) [2, 5].
Env, synthesized as polyprotein precursor gp160, is cleaved by a cellular protease into
mature proteins gp120, the surface glycoprotein (SU), and gp41, the trans-membrane
glycoprotein (TM) (Fig. 1) [2, 6].
3.2.2.   Regulatory genes of HIV-1
The HIV-1 regulatory genes tat and rev encode transactivator proteins essential for
replication. Tat (transactivator of transcription) is a 15-kDa transcription factor consisting
of several domains including a RNA binding domain and a nuclear localization signal
(NLS). The basal transcription activity from the HIV-1 LTR is very low. The interaction of
Tat with its respective transactivation response RNA element (TAR) results in the
phosphorylation of the C-terminal domain of RNA polymerase II and thus, in a dramatic
enhancement of the transcriptional activity [7-9].
Rev (regulator of expression of viral proteins) is a 21-kDa phosphoprotein, which is
involved in the translocation of transcripts from the nucleus to the cytoplasm. There are
three classes of viral mRNAs [10]:
1, unspliced genomic RNA, which functions as the mRNA for the Gag and Gag-Pol
    polyprotein precursors;
2, partially spliced mRNAs, which encode the Env, Vif, Vpu, and Vpr proteins (see
     3.2.3.);
3, fully spliced mRNAs, which are translated into Rev, Tat, and Nef (see 3.2.3.)
Binding of Rev to RRE, which is present in all unspliced and partially spliced HIV-1
RNAs, enables the transport of unspliced and partially spliced RNAs to the cytoplasm.
Thus, Rev-RRE interaction is indispensable for the virus replication [11].
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3.2.3.    Accessory genes of HIV-1
Vif (viral infectivity factor) is a 23-kDa phosphorylated protein required for the productive
infection in vivo. The protein is synthesized in the late phase of the viral life cycle during
assembly and/or maturation of virions. The requirement of Vif for efficient HIV-1
replication depends on the cell type, suggesting that its functions are specific for host
cellular factors rather than viral factors [12].
Vpr (viral protein r) is a 14-kDa protein present only in primate lentiviruses. After virus
entry the reverse transcription of the viral RNA takes place in the cytoplasm of the
target cell within the reverse transcription complex (RTC). As part of this RTC, Vpr has
an effect on the accuracy of the reverse transcription process. Vpr is also an integral
component of the pre-integration complex (PIC) and thus, participating in the nuclear
translocation of the viral DNA into non-dividing cells [13].
Vpu (viral protein u), a 16-kDa membrane protein, is expressed in infected host cells
during the late stage of infection. The two domains of Vpu are responsible for its
functions. The N-terminal trans-membrane domain appears to form ion channels and
plays a role in virion release enhancement [14]. The cytoplasmic domain is involved in
the degradation of CD4 surface molecules [15].
Nef (negative factor) is a 27- to 34-kD protein essential for viral infectivity in vivo. It acts
as a modulator of host cell pathways leading to the amplification of viral replication.
Further functions of Nef are: The downregulation of CD4 and MHC class I cell surface
molecules, the regulation of cellular activation through several kinases, and the
enhancement of HIV-1 infectivity by protecting the viral core from post-fusion
degradation [16].
3.3.    Life cycle of lentiviruses
3.3.1.    Attachment and entry
In vivo HIV-1 is mainly targeting T-cells, macrophages and dendritic cells according to
the cell surface receptors required for HIV-1 infection.  The gp120 interacts with specific
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receptors and co-receptors, like CD4, CCR5, and CXCR4 on host cells. Gp41 anchors
the gp120/gp41 complex in the membrane and is also responsible for catalyzing the
membrane fusion reaction between the viral and host cell lipid bilayers during virus
entry [6, 7].
HIV-1 can also attach to cells in a CD4-independent way, by interacting with sugars or
lectin-like domains on cell surface receptors. The chemokine receptor CCR5 is
predominantly used as co-receptor in vivo. Contrasting, additional co-receptors were
identified to support HIV-1 infection in vitro [17, 18].
Beside a receptor binding function, the glycoproteins of enveloped viruses include a
fusion protein function. The interactions of HIV-1 particles with cell surface receptors
lead to a rearrangement of gp41 and the exposure of the fusion domain induces the
fusion of the membranes to release the nucleocapsid [19]. The RTC is released
following the removal of the lipid bilayer. Subsequent to the disassembly of the virion
the nucleoprotein complex is delivered into the cell, where the reverse transcription
starts [7].
3.3.2.   Reverse transcription and nuclear import
After infection, HIV-1 converts its RNA genome into double-stranded DNA. In HIV-1, the
priming occurs at a purine-rich sequence known as the central PPT (cPPT). RNAseH
removes the tRNA bound to the primer-binding site and second-strand transfer takes
place.  The synthesis stops at the central termination signal (CTS). Since the CTS is 3’
of the cPPT, about 100nts of the plus-strand DNA are displaced, resulting in the
formation of a “DNA flap”. It supports the nuclear import of the PIC to the nucleus [7].
The PIC consists of the viral DNA/DNA double-strand forms, MA, IN, Vpr viral proteins,
and cellular factors. The nuclear import is triggered by the interaction of NLS with
specific cell proteins [20].
3.3.3.   Integration and synthesis of viral proteins
Subsequent to the nuclear import of the viral PIC, IN catalyzes the stable insertion of
the viral DNA into the host cell genome. The integration is mainly directed by
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interactions between the PIC and the chromatin. Recently it was shown, that the
integration of HIV-1 does not occur completely randomly, but favors sites of active
transcription and symmetric sequences [21]. Following the integration into the host
genome, the provirus serves as a template for the synthesis of the viral RNAs (see
3.2.2.).
3.3.4.    Virion assembly, release and maturation
The assembly of HIV-1 takes place at the plasma membrane of the infected cell. Gag is
responsible for targeting and stably binding the plasma membrane. The encapsidation
of HIV-1 RNAs into virus particles is mediated by the interactions of the packaging
signal and the NC domain of Gag. The mature envelope glycoproteins are generated by
the cleavage of gp160 (see 3.2.1.). After cleavage gp41 anchors the Env complex in the
host cell membrane. The final step in the assembly process is the budding of the virus
particle from the host cell plasma membrane. Following the virus particle release, the
viral PR cleaves the Gag and Gag-Pol polyprotein precursors to generate mature
proteins. This cleavage triggers structural rearrangements leading to the maturation of
the virion [7].
3.4.    Lentiviral vector systems
Due to the fact, that HIV-1 is the most extensively studied human pathogen to date,
HIV-1 based vectors are most commonly used. Alternatively, HIV-2, EIAV, FIV, MVV,
CAEV, and BIV (see 3.1.) are considered as lentiviral vectors. However, their usage in
gene transfer is still restricted because of low titers and the limited transducibility of
human tissues [22, 23].
For reasons of biosafety, currently used HIV-1 vector systems consist of a transfer
construct including the transgene of interest, one or more packaging constructs,
encoding all proteins required for particle production and transduction of target cells,
and an envelope construct, that encodes the envelope glycoproteins [24].
The major safety issue is to avoid the generation of replication-competent retroviruses
(RCR). RCR are produced by recombination events at sites of partial homology
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between the vector’s sequences, the packaging construct, and a retroviral element in
the producer cells [25].
3.4.1.   Modification of the packaging system
The packaging system includes all HIV-1 genes required for vector particle production
and efficient transduction of target cells [24]. The initial packaging construct was
developed by Naldini et al. (1996) and is referred as the first generation packaging
cassette [26]. It consists of one plasmid that contains all HIV-1 accessory and
regulatory genes except vpu. Env is provided on a separate plasmid. The human
cytomegalovirus (hCMV) promoter drives the expression of all viral proteins required in
trans. The packaging signal ψ was deleted from the 5’ untranslated region and the 3’
LTR was substituted with a poly(A) site from the insulin gene [26].
Further investigations led to the development of the second generation packaging
system. In contrast to the packaging system of the first generation, the plasmid lacks
the sequences encoding the accessory genes.  Virus produced with the second
generation packaging is able to transduce most target cells in vitro and in vivo [27].
Since a main objective concerning lentiviral vectors is the prevention of RCR, a third
generation packaging system was developed. To reduce the possibility of
recombination events between the helper vector and the transfer construct the gag, pol,
and rev coding sequences were segregated onto separate plasmids. The requirement
for tat was overcome by the replacement of the 5’ LTR of the transfer construct with a
strong constitutive promoter (e.g. deriving from CMV or Rous sarcoma virus (RSV))
[28].
3.4.2.   Modification of the transfer construct
Self-inactivating (SIN) HIV-1 vectors were developed to improve biosafety by minimizing
the risk of generating RCR. The viral transcriptional promoter and enhancer elements
were eliminated and mutations were positioned in the U3 region of the 3’ LTR of the
vector DNA. By reverse transcription the modified 3´ LTR is duplicated in the 5’ LTR. As
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SIN vectors are devoid of their parental enhancer/promoter sequences, they lack the
ability to transcribe full-length vector RNA [25, 29].
The incorporation of cPPT and CTS elements (see 3.3.2.) accelerate the transduction
kinetics of HIV-1 vectors. Consequently, the DNA flap improves the nuclear importation
of the PIC. In addition, the incorporation of cPPT and CTS increased the transduction
efficiency by 3-10-fold in a variety of cells [24].
The RRE permits the transport of viral RNAs by interaction with the Rev protein, which
is critical in producing high-titer virus. In a variety of vectors it has been replaced by
homologous nuclear export signals such as the Mason-Pfizer monkey virus constitutive
transport element (CTE) or the woodchuck hepatitis post-transcriptional response
element (WPRE). The insertion of WPRE was shown to increase the expression and
the stability of the transgenic mRNA in the target cell by 5-8 fold [22, 29].
3.4.3.    Modification of the envelope construct
Originally, the envelope was coded by HIV-1 env sequences. HIV-1 virions are
permissive for the incorporation of non-HIV membrane proteins, which allowed the
development of pseudotyped vectors. HIV-1 particles can be pseudotyped by envelope
glycoproteins from a variety of other viruses, including VSV. Due to the beneficial
properties, VSV-G is almost exclusively used. VSV-G stabilizes vector particles and
therefore allows vector concentration by ultracentrifugation. HIV-1/VSV-G pseudotypes
are 20-130-fold more infectious than non-pseudotyped. VSV-G is broadening the vector
tropism dramatically and it directs the vector entry to an endocytic pathway, which
reduces the requirements for viral accessory proteins [29, 30]. An obvious drawback of
VSV-G pseudotyped envelopes is the distinct cytotoxicity during its constitutive
expression [31].
3.5.    Transduction of primary cells by lentivirus
In contrast to other retroviruses, lentiviruses do not require mitosis for efficient
integration. To date, a large diversity of dividing and non-dividing primary cells have
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been successfully transduced including cells of the hematopoietic lineage, epithelial
cells, or tumor cells (for review see [22, 24] and references therein).
The nuclear import of viral DNA as part of the PIC is the rate-limiting step in the
lentiviral life cycle. Since HIV-1 can access the nucleus before mitosis, it has been
assumed that the PIC contains proteins with NLS that are essential for the infection of
non-dividing cells. These proteins include the viral structure protein MA, the viral IN, the
viral accessory protein Vpr, and in addition the cis-acting DNA sequence cPPT [32].
Several reports prove the importance of the MA-NLS for the nuclear import of the PIC.
Mutations in the MA-NLS abolished the nuclear import function and decreased the
infection of macrophages [33, 34]. Contrasting, MA-NLS independent infection was
demonstrated [35].
The deletion of vpr resulted in a diminished transport of the viral genome to the nucleus
and a reduced infection rate of macrophages [36]. However, Vpr is only a component of
primate lentiviruses and the lack of both, Vpr and MA-NLS, does not abolish the
replication in non-dividing cells [32].
Viral IN governs the nuclear import of the PIC in a NLS-mediated way. However,
mutation studies showed a critical role for HIV-IN in viral infection of both non-dividing
and dividing cells [37, 38].
In addition, mutations in the HIV-1 genome, which prevent the formation of the DNA flap
are replication defective. Though mutations in the cPPT affect the infection of dividing
as well as non-dividing cells, it is not absolutely required for infection of non-dividing
cells, because HIV-1 based vectors lacking the cPPT are still able to transduce non-
diving cells [39, 40].
Hence, the essential factors for the successful infection of non-dividing cells are still
unidentified, since even viruses lacking any of the identified NLS still remain infectious
in non-dividing cells [41].
It was recently reported that the CA protein is a dominant determinant in the infection of
non-dividing cells. CA regulates the uncoating process due to its interaction with
cytoplasmatic factors. If incoming virions can enter the nucleus only after uncoating has
proceeded, than uncoating rather than nuclear import might be the rate-limiting step in
the infection of non-dividing cells [42].
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4.     Aim of the project
The lentiviral technology is one of the most promising tools for gene transfer to primary,
non-dividing cells. So far, limiting factors for the efficient transduction are the generation
of high-titer and non-toxic lentiviral stocks.
Therefore, the aim of this work was to evaluate if the ViraPower™ T-REx™ Lentiviral
Expression System (Invitrogen) could be routinely used for the transduction of primary
macrophages. We produced virus according to the manufacturer’s protocol and
determined the titers. In order to enhance viral titers and transduce primary
macrophages more efficiently, we optimized the original protocol for lentiviral production
in terms of using different packaging systems, scaling-up the production, and
concentrating the viral supernatants. We compared the viral preparations and their
transduction efficiencies and tested different titer determination methods for their
applicability.
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5.        Materials and Methods
5.1.   Plasmids
5.1.1.    GFP
For this study the green fluorescent protein (GFP) was used as a reporter gene. In
comparison to the wild type protein the photostability and fluorescence are improved,
due to a single point mutation (S65T) [43]. The plasmid pKC/GFP (S65T) (5515bp) [44]
was kindly provided by Dr. Thomas Czerny (FH Campus Vienna). Experiments were
additionally performed with an enhanced GFP originally cloned in the vector pmaxGFP
(Lonza).
5.1.2.    Lentiviral vectors
For the generation of the lentiviral transfer vector the plasmid pLenti4/TO/V5-DEST,
supplied in the ViraPower™ T-REx™ Lentiviral Expression System (Invitrogen), was
used as a backbone. Cloning of the expression plasmid is based on the Gateway®
Technology (Invitrogen) (Fig. 2). In brief, at first the gene of interest is cloned into an
entry vector. Consequently, the transfer to the expression vector takes place by site-
specific recombination.
In the following subchapters the features of the plasmids used for generating the entry
and the expression clones are described.
Figure 2: Schematic depiction of the Gateway® cloning system. The gene of interest is cloned into an
entry vector, where the gene is flanked by attachment sites (attL). The recombination of the attL sites with
the corresponding attachment sites of the destination vector (attR) (= LR recombination) leads to the
generation of the expression clone.
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5.1.2.1.  pENTR ™1A
Due to its suitable restriction and recombination sites pENTR™1A (Invitrogen) (for
vector map see Appendix 9.1.) was chosen as an entry vector. pENTR™1A (2717bp)
includes two site-specific recombination sites (attL1 and attL2) for recombination with
the Gateway® destination vector pLenti4/TO/V5-DEST, the ccdB gene for negative
selection in ccdB sensitive E.coli, and a kanamycin resistance gene.
5.1.2.2.  pLenti4/TO/V5-DEST
The pLenti4/TO/V5-DEST (Invitrogen) (8599bp) (for vector map see Appendix 9.2.)
contains a tetracycline-regulatable hybrid promoter consisting of the CMV promoter and
two tetracycline operator 2 sites (TetO2). It also includes elements that allow packaging
of the construct into virions (e.g. 5’ and 3’ LTRs, and the packaging signal ψ) and
reverse transcription of the viral mRNA. Furthermore it carries the ampicillin and
Zeocin™ resistance marker genes for selection of stably transduced cell lines. The
pLenti4/TO/V5-DEST is adapted for Gateway® cloning and includes two recombination
sites, attR1 and attR2, for cloning of the gene of interest from an entry clone.
Furthermore, a C-terminal tag, the V5 epitope, is provided for the detection of the
recombinant protein.
5.1.3.    Packaging plasmids
Due to biosafety, an optimized mixture of packaging plasmids is needed for the
appropriate production of lentivirus. These plasmids supply the helper functions as well
as structural and replication proteins in trans required to produce the lentivirus. In this
study two different systems of packaging were used, which are described in detail in the
following chapters.
5.1.3.1.  3rd generation packaging
For this purpose the ViraPower™ Packaging mix (Invitrogen) was used. It consists of
three different packaging plasmids in an optimized ratio. It contains pLP1 (8889bp),
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pLP2 (4180bp), and pLP/VSVG (5821bp). pLP1 comprehends the HIV-1 gag gene, the
HIV-1 pol gene as well as the HIV-1 Rev response element (RRE). pLP2 encodes the
rev gene. pLP/VSVG encodes the envelope G glycoprotein from Vesicular Stomatitis
Virus to allow the production of a pseudotyped retrovirus with a broad host range (for
vector maps see Appendix 9.3. – 9.5.).
5.1.3.2.   2nd generation packaging
Plasmids for the 2nd generation packaging system were kindly provided by Prof. E.
Muellner (MFPL, MUV). psPAX2 (10703bp) combines the functions of pLP1 and pLP2.
It includes the gag and pol genes as well as the RRE. pMD2.G (5824bp) encodes the
VSV glycoprotein (for vector maps see Appendix 9.6., 9.7.).
5.2.        Cloning
5.2.1.     Isolation of plasmid DNA
Plasmid DNA (pDNA) was isolated by alkaline lysis. 3ml of L-Broth (LB)-medium (1%
tryptone, 0.5% yeast extract, 0.5% NaCl, pH7.5) containing the appropriate antibiotic
were inoculated with a single bacteria colony and incubated o/n at 37°C. Cells were
harvested by centrifugation at 10000rpm for 2 min (Eppendorf, Centrifuge 5415D),
resuspended in 250µl P1 (50mM Tris-HCl pH7.5, 10mM EDTA pH8, 0.05mg/ml RNAse
A), and lysed by addition of 250µl P2 (0.2M NaOH, 1% SDS). The reaction was
neutralized by addition of 250µl P3 (2.55M KOAc pH 4.8) and 10µl CHCl3 and
centrifuged for 10min at 13000rpm (Eppendorf, Centrifuge 5415D). The supernatant
was collected and mixed with 0.7vol isopropanol. After 10min of centrifugation at
13000rpm (Eppendorf, Centrifuge 5415D), the pellet was washed with 70% EtOH,
dried, and resuspended in an adequate amount of 1 x TE (10mM Tris, 1mM EDTA)
buffer.
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5.2.2.  Plasmid midiprep
Plasmid DNA isolation in the scale of midipreps was performed with the JETSTAR 2.0
Midiprep Kit (Genomed) according to the manufacturer’s protocol.
5.2.3.  Determination of DNA concentration
The concentration of isolated plasmid DNA was analyzed by measuring the extinction
(OD, optical density) of a 1:100 dilution (in 1 x TE buffer) at λ=260nm with a photometer
(Gene Quant II, Pharmacia, RNA/DNA Calculator). The DNA concentration was
calculated as follows:
DNA concentration (µg/ml)=OD260 x dilution factor x multiplication factor (50 for dsDNA)
5.2.4.    Digestion of DNA with restriction enzymes
Usually about 500ng of DNA were restricted with restriction endonucleases provided by
MBI Fermentas or Invitrogen, applying 1U enzyme/1µg DNA and the according buffer.
The reaction with a final volume of 20µl was incubated at the appropriate temperature
for at least 4hrs.
5.2.5.    Ligation and transformation
A ligation reaction of 15µl contained equimolar ratios of vector and insert DNA, 1µl T4
DNA ligase and 1.5µl 10x buffer for T4 DNA ligase. The reaction was incubated for 4
hours at 15-16°C and the ligase was inactivated for 15 min at 65°C.
For the transformation chemically competent cells (protocol by M. Scott, USF,
California, USA), available as a stock at the institute, were used.
50µl competent E.coli Top10F’ (Invitrogen) and 5µl ligation reaction were incubated on
ice for 30min, followed by a heat shock at 42°C for 30sec, and then kept on ice for
5min.  450ml LB-medium were added and the reactions were incubated for 90min at
37°C on a rotary shaker (Innova 4080, New Brunswick Scientific) before plating onto
LB-plates with appropriate antibiotics.
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5.2.6.    LR recombination reaction
For the LR recombination reaction 150ng of the expression vector pLenti4/TO/V5-DEST
were mixed with 150ng of the entry clone containing the GFP cDNA. After the addition
of 2µl Gateway® LR Clonase™II enzyme mix the reaction was incubated for 18hrs at
25°C in a final volume of 10µl. Subsequently, 1µl proteinase K was added, the reaction
was incubated for 10min in a water bath at 37°C and transformed into commercial
competent OneShot® StBl3™ E.coli (Invitrogen) according to the manufacturer’s
protocol.
5.2.7.    Polymerase chain reaction (PCR)
5.2.7.1.  Primer sequences
PRIMER SEQUENCE
GFP forward 5´- ATG GTG AGC AAG GGC GAG G - 3´
GFP reverse 5´- ACT TGT ACA GCT CGT CCA TG - 3´
GFP stop-reverse 5´- TTA CTT GTA CAG CTC GTC CAT G - 3´
pENTR-sequ forward 5´- TGA CTG ATA GTG ACC TGT TCG - 3´
pENTR-sequ reverse 5´- GTA ACA TCA GAG ATT TTG AGA CAC - 3´
CMV forward 5´- CGC AAA TGG GCG GTA GGC GTG - 3´
V5 reverse 5´- ACC GAG GAG AGG GTT AGG GAT- 3´
5.2.7.2.  Standard PCR reaction
A PCR standard reaction in a final volume of 25µl contained:
10pm primer each (Invitrogen), 1 x PCR buffer (200mM TrisHCl pH8.8, 500mM KCl),
0.2mM dNTPs, 1.5mM MgCl2 and 1unit Biotaq.
Cycling conditions were as follows:
5min at 95°C for initial denaturation, followed by 30-35 cycles of 30sec denaturation,
30-40sec annealing at a temperature according to primer sequences, and
polymerization at 72°C for 1min/1000bp.
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PCR fragments for sequence analysis were amplified with a proof-reading polymerase
(Pfu DNA polymerase, Fermentas) according to the manufacturer’s protocol.
5.2.7.3.  Precipitation of PCR products by polyethyleneglycol (PEG)
The PCR reaction was replenished with water to a volume of 100µl. Then it was mixed
with 1 vol PEG6000 (24% PEG6000, 3M NaCl) and incubated at 37°C for 10min. After
centrifugation at 13000rcf at 4°C for 30min (Sigma, 1-15K) the pellet was washed twice
with 70% EtOH, dried in a vacuum concentrator (Concentrator 5301, Eppendorf) and
resuspended in an adequate amount of 1 x TE buffer.
5.2.7.4.  Sequencing of PCR products
100ng of the precipitated PCR products were analyzed by dye-terminator-sequencing
using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems)
according to the manufacturer’s protocol. The BigDye® reaction products were
precipitated with 50µl 100% EtOH and 2µl 3M NaOAc, centrifuged for 30min at RT at
18000rcf (Sigma, 1-15K), washed with 70% EtOH, dried in the vacuum concentrator
(Concentrator 5301, Eppendorf), and resuspended in 20µl H2O. Sequencing was done
with the Megabace™1000 (Molecular Dynamics), a capillary dye-terminator-sequencer.
Sequences were analyzed and aligned with the Sequence Navigator-ABI PRISM
software (Applied Biosystems).
5.2.8.    DNA gel electrophoresis
PCR products and DNA fragments were analyzed by agarose gel electrophoresis.
Samples were mixed with 1/10 volume 10x loading buffer (30% glycerol, 5mM EDTA
pH8.0, 0.25% bromphenolblue) and separated on 0.8% to 1.5% agarose gels
(containing 0.05µg/ml ethidium bromide) with 0.5x TBE buffer (5.4g Tris, 2.75g boric
acid, 0.4g EDTA in 1l H2O). The 1kb+ ladder was used as a standard. DNA fragments
were visualized with a UV-transilluminator (EAGLE EYE II, Stratagene).
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5.3.    Cell culture
5.3.1.    Cell culture reagents
*) Before use FCS has been inactivated at 56°C for 30min (except FCS for 293FT
cells).
Cells were incubated at 37°C and 5% CO2 in standard medium (DMEM + 10%FCS,
2mM L-Glu, 100µg/ml P and 100U/ml S) except where otherwise indicated.
Reagent abbreviation Art. No.
Dulbecco's Modified Eagle Medium,
High Glucose DMEM Invitrogen #41966-029
Fetal Calf Serum*) FCS Invitrogen #10270-106
L-Glutamine 200mM (100x) L-Glu Invitrogen #25030-024
Penicillin-Streptomycin, 10000U/ml
Penicillin and 10000µg/ml Streptomycin
(100x) P/S Invitrogen #15140-122
2-Mercaptoethanol 55mM (1000x) β-ME Invitrogen #31350-010
Phosphate-Buffered Saline (1x), pH 7.4 PBS Invitrogen #10010-015
Dimethyl sulfoxide DMSO Sigma       #D2650
G418 (Geneticin) Biochrom #A 2912
Non-Essential Amino Acids solution
10mM (100x) NEAA Invitrogen #11140-050
MEM Sodium Pyruvate Solution
100mM (100x) SP Invitrogen #11360-070
Opti-MEM I Reduced Serum Medium Opti-MEM Invitrogen #31985-062
Trypsin-EDTA 0.05% Invitrogen #25300-054
ZeocinTM Invitrogen #R250-05
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5.3.2.    Cell lines
5.3.2.1.  293FT cells
293FT cells (Invitrogen) are derived from the 293 cell line (ATCC #CRL-1573)
descending from primary embryonic human kidney. The E1A adenovirus gene
participates in transactivation of some viral promoters, allowing the cells to produce high
levels of protein. Furthermore the 293FT cell line stably expresses the SV40 large T
antigen controlled by the CMV promoter.
293FT cells were grown in standard medium supplemented with 10% not heat
inactivated FCS, 1x NEAA, 1xSP and 500µg/ml G418.
5.3.2.2.   2fTGH cells
The 2fTGH cell line is a mutant HT1080 human sarcoma cell line transfected with a
vector encoding a selectable marker regulated by interferon [45]. 2fTGH cells were
used for titration experiments due to their beneficial characteristics. They grow in an
adherent non-migratory manner and exhibit a doubling time in the range of 18-25hrs.
2fTGH cells were grown in standard medium.
5.3.2.3.   HeLa cells
The HeLa cell line (ATTC #CCl-2) is an immortal cell line derived from cervical cancer
cells.
HeLa cells were grown in standard medium.
5.3.3.      Freezing of cells
The cells were washed with PBS, trypsinized, and centrifuged for 5min at 1000rpm
(Hereaus Multifuge 1S, ThermoScientific). The supernatant was removed and the cells
were thoroughly resuspended in pre-cooled freezing-medium (90% FCS + 10% DMSO).
1ml aliquots were transferred into pre-cooled cryotubes and incubated for further 30min
on ice. Vials were stored at –80°C o/n and transferred into liquid nitrogen (bone
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marrow-derived macrophages (BMM)) or to a freezer at -152°C (cell lines) for long-term
storage.
5.3.4.    Thawing of cells
Cells were thawed carefully in a water bath at 37°C, transferred into 10ml DMEM and
centrifuged for 5min at 1000rpm (Hereaus Multifuge 1S, ThermoScientific). After
discarding the supernatant, the cell pellet was resuspended in a suitable volume of
appropriate medium and seeded onto cell culture dishes.
5.3.5.    Preparation of L929 conditioned medium
L929 cells (ATCC #CCL-1) grown to full confluency on cell culture dishes (Ø10cm) were
split onto 30 culture dishes (Ø 15cm). Cells were grown in standard medium until
approximately 70% confluency. The medium was removed and the cells were incubated
additional 10 days with starving medium (standard medium without FCS) under
standard conditions. Afterwards the medium was collected and filter-sterilized (Vacuum
filter, 0.22µm). Aliquots were stored at –20°C and thawed at 4°C o/n prior to use.
5.3.6.    Isolation of bone marrow-derived macrophages (BMM)
BMM were isolated and grown in standard medium for BMM (supplemented with 50µM
β-ME and 15% conditioned medium from L929 cells) [46]. Mice were sacrificed by
cervical dislocation. Tibia and femur were isolated and transferred into PBS. Bones
were cut at both ends and flushed with 1ml standard medium for BMM per bone. The
cells were pooled, resuspended and plated onto three non-tissue culture dishes (Ø
10cm). At day 3 after isolation the medium was changed. The cells were split (1:2 or
1:3) upon confluency and seeded for experiments on tissue culture dishes at day 8 after
isolation.
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5.3.7.    Isolation of thioglycollate-elicited peritoneal macrophages (PM)
Mice were injected intra-peritoneally with 2ml of one-week-old 4% Thioglycollate-
medium and sacrificed 4 days later by cervical dislocation. The peritoneum was flushed
with 8ml PBS and the obtained cells were plated onto cell culture dishes. After 2hrs
incubation period the cells were washed with PBS and fresh medium was added. PM
were grown in standard medium with 5% FCS and supplemented with 50µM β-ME.
5.4.    Production of lentivirus
5.4.1.    Transfection with Lipofectamine™ 2000
9µg ViraPower™ Packaging mix (Invitrogen) and 3µg pLenti4/TO/V5-GFP were
resuspended in 1.5ml Opti-MEM. Lipofectamine™ 2000 (3µl/µg DNA) was solubilized in
1.5ml Opti-MEM. After an incubation of 5min at RT the solutions were mixed and
incubated at RT for 20min. In the meantime 293FT cells were washed with PBS,
trypsinisized, pooled, and counted. The DNA-Lipofectamine complexes (3ml) were
plated onto 10cm cell culture dishes together with 2ml 293FT medium w/o G418. 6 x
106 293FT cells in 5ml medium were seeded onto the complexes and incubated o/n at
standard conditions. On the following day the medium containing the DNA-
Lipofectamine™ 2000-complexes was removed and replaced by standard complete
medium w/o G418. 48-72hrs after transfection the viral supernatant was harvested,
centrifuged for 5min at 1000 rpm (Hereaus Multifuge 1S, ThermoScientific), and the
supernatant was stored at –80°C.
5.4.2.    Transfection with TransIT®-LT1 Transfection Reagent
On the day before transfection 2 x 106 293FT cells were plated on 6cm cell culture
dishes. 20µl TransIT®-LT1 transfection reagent (4µl/µg DNA) were dissolved in 500µl
Opti-MEM and incubated 10-15min at RT. 5µg DNA (packaging plasmids and
respective expression clones) were added and incubated 20-25min at RT. After the
removal of the medium the TransIT®-LT1 reagent / DNA complexes were dropped onto
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the cells. 12-14 hrs post transfection the medium was removed and 293FT medium
supplemented with 30% FCS was added. On the following 3 days the medium was
collected, centrifuged (5min at 1000 rpm, Hereaus Multifuge 1S, ThermoScientific), and
stored at –80°C while fresh medium (+ 30% FCS) was added.
5.4.3.    Concentration of the lentivirus
During virus production the medium was collected on consecutive days and stored at
–80°C. The collected supernatants were thawed, pooled, and ultracentrifuged at 4°C,
24000 rpm for 1:45hrs (Sorvall Ultra Pro 80, Rotor Sorvall AH-828, DuPont
Instruments). The pellets were incubated in 200µl Opti-MEM on ice o/n to dissolve. On
the next day the pellets were resuspended and 20µl aliquots were stored at –80°C.
5.4.4.    Killing curve experiment
Due to the Zeocin™ -resistance of the pLenti4/TO/V5-DEST constructs the sensitivity of
2fTGH and HeLa cells had to be determined. Therefore 25% confluent cells plated on
10cm dishes were grown with different concentrations of antibiotics (50 - 1000µg/ml).
Cells grown with the appropriate antibiotic concentration died at day 10-14 after
antibiotic addition.
5.4.5.    Titration of the lentiviral stock
2 x 105 2fTGH and HeLa cells were plated in each well of a 6-well dish (day 1). On the
next day the lentiviral stock was thawed and 10-fold dilutions were prepared (10-2 - 10-6)
in 1ml medium. After removing the old medium, the lentiviral dilutions and 6µg/ml
hexadimethrine bromide (Polybrene®) were added. Dishes were incubated at 37°C and
5% CO2 o/n. On day 3 the medium was changed. Antibiotic selection started at day 4.
The medium was removed, the cells were washed with PBS, trypsinizied, transferred
onto cell culture dishes (Ø 10cm), and the appropriate amount of antibiotic,
corresponding to the resistance of the plasmids, was added.
Every 2-3 days the medium containing the antibiotic was changed. On day 14-16 (post
plating cells) the medium was removed, the cells were washed twice with PBS and
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stained for 10min with Crystal violet solution. The Crystal violet solution was removed
and the cells were washed twice with PBS. Blue-stained colonies were counted and the
transducing units per ml (TU/ml) were determined according to the manufacturer’s
protocol.
5.5.  Product-enhanced reverse transcriptase (PERT) assay
The PERT assay is a very sensitive method to detect reverse transcriptase (RT) activity
within the virions. It is a quantitative real-time-PCR assay, based on the enzymatic
capacity of the viral RT to synthesize DNA from RNA templates [47].
The viral supernatants were mixed 1:2 with disruption buffer (40mM Tris-HCl pH8.1,
50mM KCl, 20mM Dithiothreitol (DTT), 0.2% NP-40, 0.2% Triton X-100), incubated for
two minutes at room temperature, and stored on ice. The samples were diluted 1:1000
with the dilution buffer (20mM Tris-HCl pH7.5, 50mM KCl, 0.25mM EDTA pH8, 0.025%
Triton X-100, 50% Glycerol, 0.2mM DTT). The real-time RT-qPCR was performed at
VetOMICs (Core Facility for Research, VetMedUni Vienna). Dilutions from Moloney
murine leukemia virus (MMLV) reverse transcriptase molecules (Promega) served as
standard concentrations (10-12 – 10-5 pU/10µl). Brome mosaic virus (BMV) RNA was
used as a RNA template. The PCR reaction included:
H20 4.26µl
10 mM Tris-HCl, pH 8.3 0.25µl
25 mM KCl 0.63µl
0.175 % Triton X-100 0.24µl
200 µM each dNTPs 2.00µl
2.5 mM MgCl2 2.50µl
1 mM DTT 0.25µl
0.5µM primer BMV-forward 1.25µl
1µM primer BMV-reverse 2.50µl
0.15 µM BMV probe 0.38µl
25 nM ROX Ref. Dye 0.50µl
1.25 U AmpliTaq Gold 0.25µl
20 ng BMV RNA 5.00µl
Sample 5.00µl
25.00µl
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primer BMV-forward 5'  - GCT CGC TGG TGA TTT GAT CTT - 3'
primer BMV-reverse 5'  - CAC AAC GTT CCT ACC TGG AAC A - 3'
BMV probe
5'  - FAM-CTC TGT GTG AGA CCT CTG CTC GAG GAG A -
       TAMRA - 3'
Cycling conditions were as follows:
45min at 37°C, 10min at 95°C, followed by 45 cycles of 15sec at 95°C and 1min at
60°C.
The activity of transcribing the BMV RNA was specified as pU/10µl, measured by a
7500 Real-time PCR System (Applied Biosystems) and analyzed by SDS Software
Version 1.3.1. (Sequences Detection Software, Applied Biosystems).
5.6.    Transduction of primary cells
2 x 104 to 2 x 105 primary cells (BMM and PM) were plated in 24-, 48-, and 96-well
dishes (for more details see Table 3) and transduced with an arbitrary volume of viral
supernatant by adding 6µg/ml Polybrene®. 24 and 48hrs post transduction the
expression of GFP was checked with an ultraviolet (UV)-microscope (Diaphot 300,
Nikon). Pictures were taken with the AxioCam Hrc by Zeiss and analyzed with the
software AxioVision Release 4.6.3. (4-2007).
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5.7.  List of materials and reagents
Agrobiogen (Hilgertshausen, Germany)
Biotaq DNA - polymerase
BD Bioscience Austria (Schwechat, Austria)
Falcon™ cell culture dishes
Beckmann (Krefeld, Germany)
centrifuge adaptors, centrifuge tubes
Fermentas (St. Leon-Rot, Germany)
2´-desoxyribonukleosid-5´-triphosphate (dNTPs), Pfu-DNA Polymerase, restriction
enzymes, T4 DNA Ligase
Greiner (Kremsmünster, Austria)
cryotubes, non-tissue culture dishes
Invitrogen (Lofer, Austria)
1kb+ DNA ladder, UltraPure Agarose, Gateway® LR Clonase™II enzyme mix,
Lipofectamine™ 2000, Virapower™ Packaging Mix, chemically competent OneShot®
StBl3™ E.coli, Proteinase K, restriction enzymes, RNAse A
Merck (Vienna, Austria)
brome phenol blue, magnesium chloride, sodium chloride, sodium hydroxide,
ampicilline sodium salt, kanamycine disulfate
Mirus (Wisconsin, USA)
TransIT®-LT1 Transfection Reagent
Österreichische Alkoholhandels GmbH (Spillern, Austria)
ethanol
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Roth (Karlsruhe, Germany)
bor ic acid,  chloroform, di th iothrei to l  (DTT),  ethidium bromide,
ethylenediaminetetraacetic acid (EDTA), hydrochloric acid, isopropanol, polyethylene
glycol (PEG6000), potassium acetate, potassium chloride, sodium acetate,
Tris(hydroxymethyl)-aminomethane (Tris), tryptone, yeast extract
Sarstedt (Wr. Neudorf, Austria)
cell culture dishes, vacuum filter 0.22µm, laboratory consumables (pipette tips, tubes)
Sigma-Aldrich (Vienna, Austria)
Crystal violet solution, glycerol, nonyl phenoxylpolyethoxylethanol (NP-40),
Polybrene®, sodium dodecyl sulfat (SDS), thioglycollate, Triton X-100
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6.    Results
6.1.    Cloning strategy of the lentiviral vector
The commercial Virapower™ T-REx™ lentiviral expression system (Invitrogen) includes
the destination plasmid pLenti4/TO/V5-DEST (for details see 5.1.2., 5.1.2.2. and
Appendix 9.2.) as a backbone for the generation of the lentiviral transfer vector.
The cloning system is based on the Gateway® Technology (Invitrogen). For this
purpose firstly an entry vector is cloned, where the gene of interest is flanked by attL
recombination sites. Accordingly, this gene is inserted into the destination plasmid
containing attR sites by a LR recombination reaction, i.e. by the recombination of the L
and R attachment sites of the respective clones, catalyzed by LR Clonase™ II enzyme
(Fig. 2 and 5.2.6.).
The destination vector includes the option to append a C-terminal fusion protein (V5-
epitope), which allows the detection of the recombinant protein by anti-V5 antibodies.
Therefore, two different expression clones (pLenti4-GFP/V5 and pLenti4-GFP/ΔV5)
were created to check, if this fusion tag exerts influence on the expression of the GFP
cDNA. In the case of the clone pLenti4-GFP/V5 the GFP cDNA is tagged with the V5
epitope. The clone pLenti4-GFP/ΔV5 lacks the expression of the fusion tag by using the
stop codon of the GFP cDNA.
The plasmid pmaxGFP (for details see Appendix 9.8.), encoding the GFP from copepod
Pontellina sp., was introduced by a company as a novel bright fluorescent reporter
protein. Based on the experience in our laboratory, pmaxGFP exceeds the signal
strength of other routinely used GFP proteins. Therefore, a third expression clone,
referred to as pLenti4-maxGFP, harboring the cDNA sequence of pmaxGFP, was
generated. The aim was to assess the impact of the signal strength of the GFP
expression on the transduction results.
6.1.1.    Generation of the entry clones
The cloning of the expression vector is based on site-specific recombination (Gateway®
Technology, Invitrogen). Therefore, the generation of entry clones was required. The
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Gateway® pENTR™ Vector pENTR™1A (Invitrogen) (for details see 5.1.2.1. and
Appendix 9.1.) was used as a backbone for generating the entry clones.
In case of pENTR-GFP/V5 and pENTR-GFP/ΔV5, the entry clones for the expression
vectors pLenti4-GFP/V5 and pLenti4-GFP/ΔV5, respectively, the GFP cDNA (720bp)
was amplified by Pfu-polymerase using the pKC/GFP (S65T) DNA as a template and
the primers GFP forward, reverse and GFP stop-reverse, respectively (Fig. 3).
Figure 3: Primer binding sites for the amplification of the GFP cDNA. Amplification with the primers GFP
forward / GFP stop-reverse (indicated by arrows) produced fragments for cloning the entry clone resulting
in the final expression clone without the V5 epitope tag. Amplification with the primers GFP forward / GFP
reverse produced fragments for cloning the entry clone resulting in the final expression clone including
the V5 epitope tag.
In terms of pENTR-maxGFP, the entry clone for the expression vector pLenti4-
maxGFP, the GFP cDNA was isolated by enzymatic restriction of the original plasmid
with Eco47III and XhoI (see Appendix 9.8.).
The precipitated amplification products for generating pENTR-GFP/V5 and pENTR-
GFP/ΔV5 were ligated into the blunt ended entry vector pENTR™1A (XmnI/EcoRV).
cDNA fragments derived from pmaxGFP were ligated into pENTR™1A (XmnI/XhoI).
The ligated plasmids were transformed into E.coli Top10F’ and the bacteria were grown
on LB plates by kanamycin selection. A PCR screen, using the primers GFP forward,
reverse and stop-reverse, respectively (Fig. 3), identified positive pENTR-GFP/V5 and
pENTR-GFP/ΔV5 clones. A restriction analysis (AvaII/PvuI) revealed two fragments
(2249 and 715 bp) for positive clones (Fig. 4). Positive pENTR-maxGFP clones were
identified by enzymatic restriction (BanII) of the pDNA, giving rise to four fragments
(1050, 770, 700, and 430 bp) (Fig. 5).
TAA
GFP forward GFP stop-reverse
GFP forward GFP reverse
GFP cDNA
Fragment for pENTR-GFP/ΔV5
Fragment for pENTR-GFP/V5
ATG
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Figure 4: Restriction analysis of pENTR-
GFP/V5. Samples were digested with AvaII and
PvuI. Lane 1: Pattern of a negative clone where
the GFP cDNA fragment was not integrated;
Lane 2: Pattern of a positive clone (#9) giving
rise to two fragments (2249 and 715bp); M:
1kb+ ladder
Figure 5: Restriction analysis of pENTR-
maxGFP. Samples were digested with BanII.
Lane 1: Pattern of a positive clone giving rise to
four fragments (1050, 770, 700, and 430bp);
Lane 2: Pattern of a negative clone where the
GFP cDNA fragment was not inserted; M: 1kb+
ladder   
Subsequently, the integrity of the sequences of the positive clones was confirmed by
sequence analysis using the primers pENTR-sequ forward and reverse, which hybridize
sequences of pENTR™1A next to the insertion site of the cloned fragments. Sequences
were aligned to the published vector sequence (http://tools.invitrogen.com/content/sfs
/vectors/pentr1a_seq.txt) and to the GFP mRNA sequence (GenBank Access. No.
DR631190.1). The sequence of maxGFP cDNA is unpublished but the sequence taken
from the original vector showed a high homology to the GFP mRNA of Pontellina
plumata (GenBank Access. No. AY268072.1).
Following clones were chosen as entry vectors for the final expression clones: pENTR-
GFP/V5 – clone #9, pENTR-GFP/ΔV5 – clone #13, and pENTR-maxGFP – clone #1.
6.1.2.    Generation of the expression clones
The expression clones pLenti4-GFP/V5, pLenti4-GFP/ΔV5, and pLenti4-maxGFP were
created by a recombination reaction between the attR sites of the pLenti4/TO/V5-DEST
destination vector and the attL sites of the respective entry clones (Fig. 6), followed by
the transformation into OneShot® StBl3™E.coli.
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Figure 6: Recombination region of pLENTI4/TO/V5-DEST. The shaded region corresponds to the
sequences that are replaced by the sequences of the entry clone by the recombination event. The
binding sites for the primers used for the sequence analyses (CMV forward / V5 reverse) are depicted.
The V5 epitope is only expressed in the expression clone pLenti4-GFP/V5.
A PCR screen, using either primers binding the GFP cDNA sequence (GFP forward,
reverse and stop-reverse, respectively) (Fig. 3) or primers binding vector sequences
adjacent to the integration site (CMV forward and V5 reverse) (Fig. 6) was performed to
identify positive clones. The plasmid DNA of putative positive clones was isolated and
restricted with AvaI or EcoRV. Positive clones gave rise to four fragments (5557, 1515,
596, and 20bp) or two fragments (6885 and 795bp), respectively (Fig. 7).  In case of
pLenti4-maxGFP, positive clones restricted with PvuII showed three fragments of 4991,
2513, and 795bp (Fig. 8). Subsequently, the correctness of the sequences of the
positive expression clones was confirmed by sequence analysis using the primers CMV
forward and V5 reverse.
Sequences were a l igned to the publ ished vector  sequence
(https://www.lablife.org/ct?f=c&a=viewvecseq&vectorid=91). The GFP cDNA sequence
was aligned as described before (6.1.1.)
Following clones were chosen as final expression clones: pLenti4-GFP/V5 – clone #16,
pLenti4-GFP/ΔV5 – clone #29, and pLenti4-maxGFP – clone #20.
attR1 attR2
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Figure 7: Restriction analysis of pLenti4-GFP/
V5 and ΔV5. Lane 1 and 2: Pattern of positive
clones (#16 and #32) digested with AvaI giving
rise to four fragments (5557, 1515, 596, and
20bp); Lane 3 and 4: Pattern of positive clones
(#16 and #32) digested with EcoRV giving rise
to two fragment (6885 and 795bp); M: 1kb+
ladder
Figure 8: Restriction analysis of pLenti4-
maxGFP. Samples were digested with PvuII.
Lane 1: Pattern of a positive clone giving rise to
three fragments (4991, 2513, and 776bp); M:
1kb+ ladder
To test the expression of GFP, 6 x 106 293FT cells were transfected with the expression
vectors pLenti4-GFP/V5, pLenti4-GFP/ΔV5, and pLenti4-maxGFP, respectively, using
Lipofectamine™ 2000. 24-36hrs after transfection the expression of GFP was visualized
using UV microscopy. At least 90% of the cells were successfully transfected
independent of the transfected expression vector. Nevertheless, the intensity of the
GFP expression was stronger in cells transfected with pLenti4-maxGFP, compared to
the other constructs (Fig. 9, page 47).  These observations were reproducible in at least
three independent experiments. The use of HeLa cells for transfection instead of 293FT
cells gave comparable results. Thus, the superior signal strength of the reporter protein
encoded by maxGFP cDNA can be beneficial, if a low or moderate transduction
efficiency is expected. In terms of pLenti4-GFP/V5 and pLenti4-GFP/ΔV5 no
reproducible significantly different expression levels were observed.  Hence, the V5
epitope does not seem to affect the expression of the gene of interest.
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6.2.        Separation of the plasmids included in the ViraPower™ Packaging Mix
The production of infectious virus particles is based on the co-transfection of the
expression clone and packaging plasmids encoding proteins responsible for virus
assembly and encapsidation. The Virapower™ T-REx™ lentiviral expression system
(Invitrogen) includes the plasmids for the 3rd generation packaging, namely pLP1, pLP2,
and pLP/VSV-G (for details see 5.1.3.1. and Appendix 9.3. – 9.5.)
These plasmids are originally provided by the company as a mixture with a not
indicated ratio of the respective plasmids. To transfect cells with a defined ratio of
packaging and envelope plasmid DNA, the plasmid-mix was split. Therefore, the pDNA
of the packaging mix was transformed into E.coli Top10F’. The plasmids were
discriminated by the differing restriction pattern obtained by the enzymatic digestion
with EcoRI (Fig. 10).
Figure 10: Restriction analysis of pLP1, pLP2, and
pLP/VSVG. Samples were digested with EcoRI. Lane 1:
Pattern of a positive pLP1 clone giving rise to three
fragments (4335, 4153, and 402bp); Lane 2: Pattern of a
positive pLP2 clone giving rise to two fragments (3869
and 311bp); Lane 3: Pattern of a positive pLP/VSVG
clone giving rise to two fragments (4153 and 1668bp); M:
1kb+ ladder
6.3.        Production of lentivirus using the 3rd generation packaging
For the Virapower™ T-REx™ Lentiviral Expression System (Invitrogen) the use of the
3rd generation packaging is recommended. Virus was produced according to the
manufacturer’s protocol. 6 x 106 293FT cells were transfected by lipofection with
Lipofectamine™ 2000 (5.4.1.) with the 3rd generation packaging mix and the expression
vectors pLenti4-GFP/V5 and pLenti4-GFP/ΔV5, respectively. 10ml viral supernatant
were harvested, aliquoted, and stored at –80°C. The determination of the lentiviral titer
was performed by the selection of stably transduced cells using Zeocin™ as a selection
agent. A preliminary killing curve experiment revealed the minimum concentration of
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Zeocin™ needed for the efficient killing of untransduced cells. Consequently, 100µg/ml
Zeocin™ were used for the titering experiments. The titer of the lentiviral stock was
calculated as transforming units (TU)/ml.
For the determination of the titer of preparation (Prep) A (transfected with pLenti4-
GFP/V5) and Prep B (transfected with pLenti4-GFP/ΔV5) the cell line 2fTHG was used.
Prep A showed a titer of 5 x 103 TU/ml and Prep B showed a titer of 9.7 x 103 TU/ml
(Table 1, page 40). A repetition of the titering experiment demonstrated the
reproducibility of the results.
According to the protocol a titer of at least 5 x105 TU/ml should be achievable. Since
our titers were about one to two logs beneath the expected values, we decided to
modify the original protocol by introducing optimization steps to the virus production
procedure.
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6.4.    Optimization of the lentivirus production
To improve the titer levels several approaches for optimizing the virus production were
performed. These approaches considered parameters like the packaging system, the
transfection method, the cell density and the collection of the viral supernatant. Since
the 2nd generation packaging is still the most widely and successfully used system in
lentivirus production, we co-transfected 293FT cells with the expression clone pLenti4-
GFP/V5 and the packaging plasmids psPAX2 and pMD2.G (for details see 5.1.3.2. and
Appendix 9.6., 9.7.). A modified protocol of the TransIT®-LT1 Transfection Reagent
(see 5.4.2.) was used for lipofection according to an established protocol from the
laboratory of Prof. E. Muellner (MFPL, MUV). A total of 18ml viral supernatant per virus
preparation were collected on three consecutive days and were frozen at -80°C. The
pooled supernatants of each preparation were concentrated by ultracentrifugation. All
titers were determined using 2fTGH cells. In table 2 the different approaches (Prep) 1–5
are listed displaying the variations with respect to the standard procedure (Prep 1):
Table 2: Approaches for the optimization of the virus production. The standard procedure is given for
Prep 1. For Prep 2 – Prep 5 the variations of the standard procedure are indicated.
(s.p.) according to standard procedure
The repetition of the virus production according to Prep 5 gave reproducible results. As
a consequence, the following virus preparations were produced according to the last
approach (Prep 5).
Procedure
 Prep 1            
(standard procedure) Prep 2 Prep 3 Prep 4 Prep 5
number of 
transfected cells
2 x 10e6 cells plated on 
day before transfection s.p. s.p.
1 x 10e6 cells plated on 
day before transfection
4 x 10e6 cells plated 
on day of transfection
packaging system 2nd generation 3rd generation s.p. s.p. s.p.
transfection 
procedure
DNA-complexes 
dropped onto cells s.p. s.p. s.p.
 cells seeded onto 
DNA-complexes
storage of viral 
supernatants stored at -80°C s.p. stored at 4°C s.p. s.p.
viral titer (TU/ml) 4.5 x 10e3 1.4 x 10e3 3.2. x 10e4 3.75 x 10e4 1.8 x 10e5 
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6.5.       Optimization of the virus production by the scale-up and concentration of
             the virus preparations
For the efficient transduction of primary non-dividing cells a high number of infectious
virus particles is needed. Thus, a considerable amount of viral supernatant is required
to perform several transduction experiments, especially if the needed multiplicity of
infection (MOI) is only achievable by increasing the inoculum volume.
To achieve sufficient amounts of concentrated viral supernatants the scale of the virus
preparation was increased. A total amount of 3.6 x 108 and 1.2 x 108 293FT cells were
transfected in 15cm cell culture dishes with the expression clones pLenti4-GFP/V5 and
pLenti4-maxGFP, respectively.  According to Prep 5 (see 6.4.) the 2nd generation
packaging was used for the transfection reaction. The amounts of pDNA used for the
transfection were adapted to the cell culture dish surface area. The viral supernatants
were harvested, ultracentrifuged, and resuspended in an appropriate amount of Opti-
MEM. The titering of Prep C  (pLenti4-GFP/V5) and D (pLenti4-maxGFP) using 2fTGH
cells revealed 4.9 x 105 TU/ml and 1.65 x 105 TU/ml, respectively.
In case of Prep D the determination of the titer was also performed with HeLa cells. A
preliminary killing curve experiment resulted in an optimal concentration of 50µg/ml
Zeocin™. Titration with HeLa showed a titer of 4.4 x 106 TU/ml.
Prep E (pLenti4-maxGFP) was produced as described for Prep D with a total amount of
7.2 x 107 293FT cells using 10 cm cell culture dishes. The titer was determined using
2fTGH and HeLa cells and revealed 2 x 105 TU/ml and 4.2 x 105 TU/ml, respectively.
Results are summarized in Table 1.
6.6.    Influence of the concentration by ultracentrifugation on the viral titer
Concentrated viral preparations facilitate the transduction of cells with an optimal titer by
using a minimal inoculum volume. Thus, we assessed the effective impact on the titer
and the recovery rate of infectious virus particles, if the viral preparations were
concentrated by ultracentrifugation. Furthermore, a second parameter, i.e. the use of
the 2nd versus the 3rd generation packaging system was included in the experimental
design. The virus was produced in a small scale according to the protocol of Prep 5
(see 6.4.). Thus, 4 x 106 293FT cells per 6cm dish were transfected with the expression
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clones pLenti4-GFP/V5 (Prep F, I, L, O), pLenti4-GFP/ΔV5 (Prep G, J, M, P), and
pLenti4-maxGFP (Prep H, K, N, Q). For the preparations F, G, H, L, M, N the 2nd
generation packaging and for the preparations I, J, K, O, P, Q the 3rd generation
packaging was applied. Two identical charges of transfections were done for each
expression clone and the respective packaging system. Viral supernatants of the first
charge (Prep F – K) were collected, aliquoted and stored at –80°C, whereas
supernatants of the second charge (Prep L - Q) were concentrated by
ultracentrifugation before storing the aliquots at -80°C. Titer determination was
performed using 2fTGH and HeLa cells.
The results of these experiments are summarized in Table 1. In brief, in all cases the
concentration by ultracentrifugation led to increased titer values, although to a variable
extent (4 – 55-fold). The recovery rate also showed a high variability (7 – 91 %). Titer
values for preparations performed with plasmids of the 2nd generation packaging always
exceeded those achieved with the 3rd generation packaging system.
6.7.    Evaluation of the quality of the virus preparations
A certain amount of infectious virus particles is needed to achieve an efficient
transduction of cells. Hence, it is valuable to determine the quality of a virus preparation
in order to predict the transduction efficiency with respect to reproducible results using
different preparations.
A common method is the determination of the viral titer by selecting for stably
transduced antibiotic-resistant cells. For several preparations (Prep D, E, L - Q) we
performed these experiments using two different cell lines, i.e. 2fTGH and HeLa.
Titering using HeLa cells constantly revealed higher titer values than those obtained
when using 2fTGH cells (Fig. 11) and notably influenced the calculation of the MOI
(Table 3, page 46).
Ideally, the titer determination of a virus preparation is done on the same cell line, which
is used in the experimental setup. When working with primary cells the titering has to be
performed with other cell lines owing a completely different transduction capacity. Thus,
we tried to assess the quality of the viral preparations directly by circumventing the
procedure of the titer determination. For this purpose we measured the reverse
transcriptase (RT) activity, hence the amount of functional virus particles, in the lentiviral
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supernatants (Prep A – Q) by a PERT assay analysis. Values for the RT activity
(pU/10µl) of the respective viral supernatants are shown in Table 1. The effective RT
activity per transduction reaction is shown in Table 3. The values obtained for the RT
activity were in accordance with the results of the titering experiments (Fig. 11).
Therefore, the PERT assay analysis is a cost- and time-effective alternative to estimate
the quality of a virus preparation.
Figure 11: Comparison of the viral titers obtained by selecting stably transduced cells with the RT activity
of the respective viral supernatants. Values obtained by titering using 2fTGH and HeLa cells are scaled to
the left y-axis. Values of the RT activity obtained by the PERT assay analysis are scaled to the right y-
axis.
6.8.   Lentiviral transduction of primary cells
BMM and PM were isolated according to their respective protocols and an appropriate
amount of cells was seeded onto 96-, 48-, and 24-well cell culture dishes (Table 3). On
the following day the media was replaced by variable amounts of the supernatants
derived from the different virus preparations (Table 3). Polybrene® (6µg/ml), a polymer,
which increases the infectivity of retroviruses [48] was added. 24hrs later the viral
supernatants were discarded and complete medium was added. 36 and 48hrs post
infection the cells were checked for the expression of GFP and cell viability. The results
of the transduction experiments are summarized in Table 3. Representative examples
of transduced primary macrophages are shown in Fig. 12.
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Table 3 (next page): Overview of transduced primary cells.
GFP expression: (-) missing, (+) weak, (++) moderate, (+++) strong; cell viability: (1) not impaired, (2)
impaired, (3) strongly impaired; (n.d.) not determined; (vol) inoculum volume
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    Table 3
prep celltype well cell density vol. expression cell health MOI (2fTGH) MOI (HeLa) RT activity (pU)
A BMM 96 2 x 10e4 50µl - 1 0.01 n.d. 7.4 x 10e12
100µl - 1 0.03 n.d. 1.5 x 10e13
B BMM 96 2 x 10e4 50µl - 1 0.02 n.d. 5.9 x 10e12
100µl - 1 0.05 n.d. 1.2 x 10e13
C BMM 24 2 x 10e5 20µl - 1 0.05 n.d. 4.4 x 10e13
40µl - 2 0.1 n.d. 8.9 x 10e13
100µl + 3 0.25 n.d. 2.2 x 10e14
96 2 x 10e4 50µl + 3 1.23 n.d. 1.1 x 10e14
100µl +/++ 3 2.45 n.d. 2.2 x 10e14
PM 48 2 x 10e5 20µl + 2 0.05 n.d. 4.4 x 10e13
50µl + 2 0.12 n.d. 1.1 x 10e14
100µl + 2 0.25 n.d. 2.2 x 10e14
200µl + 3 0.49 n.d. 4.4 x 10e14
D BMM 24 2 x 10e5 20µl + 1 0.02 0.44 3.6 x 10e13
40µl ++ 1 0.03 0.88 7.2 x 10e13
80µl +++ 2 0.07 1.76 1.5 x 10e14
120µl +++ 3 0.1 2.64 2.2 x 10e14
96 2 x 10e4 50µl ++/+++ 2 0.41 11 9.1 x 10e13
100µl ++/+++ 3 0.83 22 1.8 x 10e14
PM 48 2 x 10e5 20µl + 2 0.02 0.44 3.6 x 10e13
40µl +/++ 2 0.03 0.88 7.2 x 10e13
80µl ++ 2 0.07 1.76 1.5 x 10e14
120µl ++ 3 0.1 2.64 2.2 x 10e14
E BMM 24 2 x 10e5 20µl -/+ 1 0.02 0.04 1.7 x 10e13
80µl + 2 0.08 0.17 6.6 x 10e13
120µl + 2 0.12 0.25 9.9 x 10e13
96 2 x 10e4 50µl +/++ 2 0.5 1.05 4.1 x 10e13
100µl +/++ 3 1 2.1 8.2 x 10e13
PM 96 4 x 10e4 5µl - 2 0.03 0.05 4.1 x 10e12
10µl + 2 0.05 0.11 8.2 x 10e12
1 x 10e5 5µl -/+ 2 0.01 0.02 4.1 x 10e12
10µl -/+ 2 0.02 0.04 8.2 x 10e12
F BMM 96 2 x 10e4 100µl - 1 <0.01 n.d. 1.7 x 10e12
G BMM 96 2 x 10e4 100µl - 1 <0.01 n.d. 1.6 x 10e12
H BMM 96 2 x 10e4 100µl - 1 <0.01 n.d. 2.9 x 10e12
I BMM 96 2 x 10e4 100µl - 1 <0.01 n.d. 7.7 x 10e11
J BMM 96 2 x 10e4 100µl - 1 <0.01 n.d. 3.0 x 10e11
K BMM 96 2 x 10e4 100µl - 1 <0.01 n.d. 7.7 x 10e11
L BMM 96 2 x 10e4 5µl - 1 <0.01 0.01 1.1 x 10e12
10µl - 1 <0.01 0.03 2.3 x 10e12
20µl - 1 <0.01 0.06 4.5 x 10e12
50µl + 1 - 2 0.02 0.14 1.1 x 10e13
M BMM 96 2 x 10e4 5µl - 1 <0.01 <0.01 3.4 x 10e11
10µl - 1 <0.01 0.02 6.8 x 10e11
20µl - 1 <0.01 0.03 1.4 x 10e12
50µl -/+ 1 - 2 0.01 0.08 3.4 x 10e12
N BMM 96 2 x 10e4 5µl - 1 <0.01 0.02 1.6 x 10e12
10µl - 1 0.02 0.04 3.1 x 10e12
20µl + 2 0.03 0.08 6.3 x 10e12
50µl - 2 - 3 0.08 0.2 1.6 x 10e13
O BMM 96 2 x 10e4 5µl - 1 <0.01 <0.01 1.5 x 10e11
10µl - 1 <0.01 <0.01 3.1 x 10e11
20µl - 1 <0.01 0.01 6.2 x 10e11
50µl + 2 - 3 <0.01 0.03 1.5 x 10e12
P BMM 96 2 x 10e4 5µl - 1 <0.01 <0.01 1.7 x 10e11
10µl - 1 <0.01 <0.01 3.3 x 10e11
20µl - 1 <0.01 0.02 6.7 x 10e11
50µl + 2 - 3 <0.01 0.04 1.7 x 10e12
Q BMM 96 2 x 10e4 5µl - 1 <0.01 <0.01 1.1 x 10e12
10µl - 1 <0.01 <0.01 2.2 x 10e12
20µl - 1 <0.01 0.01 4.5 x 10e12
50µl - 3 <0.01 0.03 1.1 x 10e13
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Figure 9: Transfection of 293FT cells with the expression vector.
6 x 106 cells were transfected with 3µg of (A) pLenti4-GFP/ΔV5 and (B) pLenti4-maxGFP, respectively.
36hrs after transfection, more than 90% of the cells were successfully transfected. The intensity of the
GFP expression was considerably higher for cells transfected with pLenti4-maxGFP. Results for cells
transfected with pLenti4-GFP/V5 were comparable to (A).
Figure 12: Transduction of primary macrophages.
2 x 105 BMM were transduced with 40µl (A) and 120 µl (B) of Prep D, respectively. More than 90% of the
cells were successfully transduced in both cases. However, cells inoculated with a higher volume showed
a strongly impaired viability (B).
2 x 105 PM were transduced with 40µl (C) and 80 µl (D) of Prep D, respectively. Approximately 40% (C)
and 80% (D) cells showed a weak to moderate expression of GFP. In both cases an impairment of the
cell viability was observed.
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7.          Discussion
The lentivirus technology is one of the most promising tools for gene delivery to primary
cells. The generation of high-titer and non-toxic lentiviral stocks is crucial for the
successful infection especially of differentiated, non-dividing cells. In this work we
wanted to evaluate if a new lentiviral vector system – the ViraPower™ T-REx™
Lentiviral Expression System (Invitrogen)  – meets demands for the routinely use in
transduction of non-dividing cells.
The production of virus according to the manufacturer’s protocol resulted in low titers,
i.e. 5 - 9.7 x 103 TU/ml. As a consequence, independent of the inoculum volume the
calculated multiplicity of infection (MOI) was low (0.013-0.49) and the infected
macrophages failed to express readily detectable GFP.
Due to the stability of VSV-G pseudotypes, the concentration by ultracentrifugation of
HIV-1 based lentiviral vectors is widely used to augment titers [30].  We compared
equally produced concentrated and unconcentrated preparations and observed both
varying increase of the titer (4 - 55-fold) and recovery rates (7 - 91%). Our results are in
accordance with published data, wherein the variability is attributed to the conditions of
the concentration procedure and the size of the transfer vector [49-51].
The efficient production of lentivirus by means of the 3rd generation packaging was
proven previously [28]. However, in some reports the direct comparison of the
packaging systems showed clear advantages in favor of the 2nd generation packaging
[50, 52]. To assess the influence of the packaging in our system we analyzed titer levels
and the transduction capacity of virus preparations differing only in the applied
packaging. We showed, that viruses transfected with the 2nd generation packaging
achieved explicitly higher titers with an increase in the range of 9.5 – 33x compared to
the 3rd generation group. The refinement in terms of biosafety by introducing an
additional packaging plasmid might negatively influence virus particle production.
We determined the titer of our virus preparations by the selection of antibiotic-resistant,
thus virus-DNA containing cell colonies. Selection for stable integration of virus-DNA is
based and therefore dependent on transduction of the cells used for titering. The
conditions of the transduction process (e.g. inoculum volume, sensitivity of target cells,
cell density, incubation period) are crucial for titer levels and the subsequent calculation
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of the MOI. More than 50-fold difference in titer level or MOI was reported for the same
vector stock using different cell numbers or incoculum volumes [53].
Since HT1080 cells were recommended by the original protocol for optimal titration
results we used 2fTGH cells, descending from HT1080, as the standard cell line for the
titration experiments. However, the titration of the same virus preparations with HeLa
cells revealed reproducibly higher titer levels (18.3–fold, median value) leading to strong
discrepancies between calculated MOI values dependent on the cell line used for
titration. Thus, with this titering method we could not specify standard MOI values,
which guarantee reproducible transduction results.
Alternatively, p24 antigen ELISA or RT-PCR-analysis of virus-DNA and –RNA in
transduced cells or supernatants, respectively, are routinely used for titer determination.
Titers assessed by DNA-analysis provide a reliable estimate, whereas RNA analysis as
well as p24 titers are rather poor in predicting transduction efficiency, due to
overestimation by non-functional vector particles [54, 55].
As an alternative method to assess the quality of our virus preparations we applied the
PERT assay analysis for quantitative detection of the RT activity [56, 57]. The RT
activity was measured directly on the harvested viral supernatant, thus avoiding
influences by cell transduction. By transducing primary cells (BMM and PM) we
revealed moderate to strong GFP expression, if cells were inoculated with at least 1 x
1014 pU of RT activity. Furthermore, beneath an activity of 1013 pU the cell viability was
not essentially impaired. With increasing activity the cell health dropped drastically,
which referred rather to the increase of the inoculum volume than to RT activity levels.
In our study the PERT assay turned out to be a valuable tool to assess, if a virus
preparation fulfills the requirements for the efficient transduction of macrophages, i.e.
transduction with a minimum of 1 x 1014 pU of RT activity in a preferably small inoculum
volume.
In summary, we showed the successful transduction of primary macrophages, provided
that the transduction occurs with a minimum RT activity. For the routinely use of this
lentiviral expression system the optimization of the original protocol is indispensible.
Virus preparations must be prepared in a large scale to assure sufficient amounts
following the concentration of the virus. A repeated concentration of the virus might be
required in order to transduce sensitive cells with small volumes of highly concentrated
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virus. Furthermore, we showed, that the measurement of the RT activity in the viral
supernatants by the PERT analysis proved to be a time and cost saving tool for the
reliable prediction of the transduction efficiency.
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9.      Appendix
9.1.    Vector map of pENTR TM
Vector map provided by Invitrogen (www.invitrogen.com)
56
9.2.    Vector map of pLenti4/TO/V5-DEST
Vector map provided by Invitrogen (www.invitrogen.com)
57
9.3.    Vector map of pLP1
      EcoRI cuts at bases 1333, 5668, and 6069
Vector map provided by Invitrogen (www.invitrogen.com)
58
9.4.    Vector map of pLP2
   EcoRI cuts at bases 176 and 4045
Vector map provided by Invitrogen (www.invitrogen.com)
59
9.5.     Vector map of pLP/VSVG
  EcoRI cuts at bases 1333 and 3001
Vector map provided by Invitrogen (www.invitrogen.com)
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9.6.    Vector map of psPAX2
                   
Vector map provided by Addgene Vector Database (http://www.addgene.org/12260)
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9.7.    Vector map of pMD2.G
          
Vector map provided by Addgene Vector Database (http://www.addgene.org/12259)
62
9.8.    Vector map of pmaxGFP
Vector map provided by Lonza (www.lonzabio.com)
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